Growing awareness of personal health and wellness presents numerous long-term tailwinds for healthcare companies. However, issues such as inventory destocking post-COVID-19 have acted like speed bumps, persistently constraining the industry’s growth momentum. This has also led to the recent underwhelming performance of healthcare stocks. Despite this, elite companies always find ways to achieve profitable growth amidst challenges. Next, we will analyze one promising stock with enduring advantages and examine two stocks that might be worth considering for sale currently.
Regeneron Pharmaceuticals (REGN) focuses on developing and commercializing drugs for serious diseases, with its product pipeline covering areas such as ocular diseases, allergies, cancer, and more. However, over the past two years, the company’s annual sales growth rate was only 5.9%, lagging behind many healthcare peers. Regeneron’s substantial revenue base makes it difficult to generate significant incremental demand. Meanwhile, over the past five years, the company’s cost growth has outpaced its revenue growth, leading to a 21.4 percentage point decline in its adjusted operating margin. Furthermore, the trend of diminishing returns on capital suggests that the profit pools established earlier may be depleting. At the current share price of $564.50 and a forward P/E ratio of 15.5x, the growth momentum appears insufficient.
Revvity (RVTY) provides health science technologies and services covering the entire process from drug discovery to development, and from diagnosis to cure. However, the company faces growth challenges. Over the past two years, it has lacked organic revenue growth, indicating it may be overly reliant on acquisitions to drive expansion rather than internal momentum. Over the past five years, due to declining sales, the adjusted operating margin has also fallen, reflecting an overall decrease in productivity. More notably, the company’s return on capital has continued to decline from an already weak level. At a share price of $83.88 and a forward P/E of 15.9x, the effectiveness of its transformation remains to be seen.
In contrast to the companies mentioned above, Medpace (MEDP) demonstrates robust health. Since its founding in 1992, the scientifically-led company has provided outsourced clinical trial management and research services to pharmaceutical, biotechnology, and medical device companies. The health of its core business is the biggest highlight: over the past two years, without relying on acquisitions, it has achieved high organic revenue growth averaging 15.7%, proving strong internal growth capability. Over the past five years, through active share buybacks, the company’s earnings per share growth has even outpaced revenue growth, creating additional value for shareholders. Most notably, its high return on capital of 44.1% leads the industry. Although the stock price is high at $495.29 per share, corresponding to a forward P/E ratio of 40.4x, its strong fundamentals provide solid support for the valuation.
